Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Sequential f-IPV and bOPV
NCT01813604Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 2012
- Primary completion
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trivalent inactivated polio vaccine and bivalent oral poliovirus vaccine in poliomyelitis (5 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Seroconversion against poliovirus types 1, 2 and 3 at 18 weeks. Started Nov 2012; status: completed.
02
Drugs
trivalent inactivated polio vaccinebivalent oral poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT01813604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813604.